Edition:
United Kingdom

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
7:08pm BST
Change (% chg)

$-0.03 (-1.33%)
Prev Close
$2.26
Open
$2.26
Day's High
$2.26
Day's Low
$2.21
Volume
11,491
Avg. Vol
24,538
52-wk High
$4.83
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Cardiome Pharma - William Hunter, President & CEO, Justin Renz, CFO Purchased Total Of 210,000 Common Shares Of Co On TSX And Nasdaq On March 26
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Cardiome Pharma Corp ::CARDIOME PHARMA - WILLIAM HUNTER, PRESIDENT & CEO, JUSTIN RENZ, CFO PURCHASED TOTAL OF 210,000 COMMON SHARES OF CO ON TSX AND NASDAQ ON MARCH 26.  Full Article

Health Canada Accepts Cardiome's Xydalba For Review
Thursday, 22 Mar 2018 

March 22 (Reuters) - Cardiome Pharma Corp ::HEALTH CANADA ACCEPTS CARDIOME'S XYDALBA NEW DRUG SUBMISSION AND GRANTS PRIORITY REVIEW.CARDIOME PHARMA CORP - EXPECTS TO RECEIVE AN APPROVAL DECISION FOR XYDALBA DURING Q3 OF 2018.  Full Article

Cardiome Pharma To Pay $2.5 Mln Termination Fee To Cipher If Proposed Arrangement Not Completed
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Cardiome Pharma Corp ::CARDIOME PHARMA-TERMINATION FEE OF $2.5 MILLION (CAD) PAYABLE BY CO TO CIPHER IN CERTAIN CIRCUMSTANCES IF PROPOSED ARRANGEMENT NOT COMPLETED - SEC FILING‍​.CARDIOME PHARMA SAYS REVERSE TERMINATION FEE OF $2.5 MILLION (CAD) PAYABLE BY CIPHER TO CO IN CERTAIN CIRCUMSTANCES, IF PROPOSED ARRANGEMENT NOT COMPLETED.  Full Article

Cipher Pharmaceuticals And Cardiome Pharma Announce Strategic Transaction For Canadian Business Portfolio Of Cardiome
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Cardiome Pharma Corp ::CIPHER PHARMACEUTICALS AND CARDIOME PHARMA ANNOUNCE STRATEGIC TRANSACTION FOR CANADIAN BUSINESS PORTFOLIO OF CARDIOME.CIPHER PHARMACEUTICALS INC - DEAL PROVIDES IMPORTANT UPFRONT AND NON-DILUTIVE CONSIDERATION OF $25.5 MILLION CAD.CIPHER PHARMACEUTICALS - ‍PROPOSED DEAL TO BE COMPLETED PURSUANT TO ACQUISITION BY CIPHER OF ALL OF CARDIOME SHARES, FOLLOWING RESTRUCTURING OF CARDIOME​.CIPHER PHARMACEUTICALS - ‍CARDIOME SHAREHOLDERS TO GET SHARES, ON A ONE-FOR-ONE RATIO, OF NEWLY CREATED CANADIAN ENTITY NAMED CORREVIO PHARMA.CIPHER PHARMACEUTICALS INC - BOARD OF DIRECTORS OF CARDIOME HAS UNANIMOUSLY APPROVED ARRANGEMENT AGREEMENT.CIPHER PHARMACEUTICALS INC - ‍EXPECTS TO FINANCE ACQUISITION WITH A COMBINATION OF CASH AND NEW DEBT​.CIPHER PHARMACEUTICALS - ‍ALL OF DIRECTORS AND SENIOR OFFICERS OF CARDIOME HAVE ENTERED INTO VOTING AND SUPPORT AGREEMENTS WITH CIPHER​.CIPHER PHARMACEUTICALS - VOTING AND SUPPORT AGREEMENTS' BY ‍ALL OF DIRECTORS AND SENIOR OFFICERS OF CARDIOME IS TO VOTE IN FAVOUR OF ARRANGEMENT​.  Full Article

Cardiome Reports Q4 Loss Per Share $0.24
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Cardiome Pharma Corp ::CARDIOME REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $7.0 MILLION VERSUS I/B/E/S VIEW $8.4 MILLION.Q4 LOSS PER SHARE $0.24.Q4 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S.  Full Article

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Cardiome Pharma Corp ::CARDIOME ANNOUNCES STRATEGIC LICENSING AGREEMENT TO COMMERCIALIZE AGGRASTAT IN RUSSIA.CARDIOME PHARMA CORP - AFFILIATE CORREVIO HAS ENTERED INTO AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WITH ZAO FIRMA EUROSERVICE.CARDIOME PHARMA - AS PER LICENSE AGREEMENT, ZAO WILL BE RESPONSIBLE FOR OBTAINING REGULATORY APPROVALS FOR AGGRASTAT FROM RUSSIA'S MINISTRY OF HEALTH.CARDIOME PHARMA CORP - ADDITIONAL TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Cardiome Q3 loss per share $0.20
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Cardiome Pharma Corp :Cardiome reports third quarter 2017 financial results.Sees fy 2017 revenue $24 million to $26 million.Q3 revenue $6.0 million versus I/B/E/S view $7.3 million.Q3 loss per share $0.20.Q3 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S.Cardiome Pharma Corp - expects existing cash and cash equivalents will be sufficient to fund its operations for at least next 12 months..  Full Article

Cardiome Pharma commercially launches Xydalba in Sweden, Finland and Republic Of Ireland​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Cardiome Pharma Corp -:Cardiome Pharma - has initiated commercial launch of Xydalba (dalbavancin hydrochloride) in Sweden, Finland and Republic Of Ireland​.  Full Article

Cardiome announces agreement with Basilea
Tuesday, 12 Sep 2017 

Sept 12 (Reuters) - Cardiome Pharma Corp ::Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel.Cardiome Pharma- under agreement, Basilea has granted cardiome an exclusive license to commercialize Ceftobiprole in 34 European countries and Israel.Cardiome Pharma Corp - Cardiome will provide Basilea with upfront payment, additional milestone payments based upon achievement of certain milestones.  Full Article

Cardiome provides U.S. regulatory update for BRINAVESS
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Cardiome Pharma Corp :Cardiome provides U.S. regulatory update for BRINAVESS.Cardiome Pharma Corp - ‍FDA advised Cardiome that data package proposed by Cardiome would not be sufficient to support a resubmission of BRINAVESS NDA​.Cardiome Pharma Corp - ‍Intends to explore every reasonable avenue available to make Vernakalant available in United States​.Cardiome Pharma Corp - ‍"We will continue to have a dialogue with FDA as we review our regulatory options" for BRINAVESS​.  Full Article